Navigation Links
New discovery brings hope to treatment of lymphatic diseases
Date:8/10/2009

LEXINGTON, Ky. (Aug. 10, 2009) − Researchers in the laboratory of Dr. Jayakrishna Ambati at the University of Kentucky have discovered the first naturally occurring molecule that selectively blocks lymphatic vessel growth. In an article in the Aug. 9, 2009 online edition of Nature Medicine, they report the identification of a new molecule known as soluble VEGFR-2 that blocks lymphangiogenesis the growth of lymphatics but not blood vessel growth.

The twin circulatory systems of mammals - blood and lymphatic - are intricately intertwined, both anatomically and functionally. Until now it has been difficult to selectively target one without affecting the other. The lymphatic vessel network is essential for transporting fluids, molecules, and immune cells. It is crucial for wound healing and immune defense. Disturbances in the lymphatics are involved in diseases as varied as lymphedema, transplant rejection, and tumor metastasis, which collectively affect hundreds of millions of people worldwide.

This article, whose lead author is Dr. Romulo Albuquerque, currently a medical student in the UK College of Medicine, showed that soluble VEGFR-2 specifically blocks lymphatic vessel growth both during development and following injury by blocking VEGF-C, a powerful lymphatic growth factor. It also reports that loss of soluble VEGFR-2 during development led to the spontaneous invasion of lymphatic vessels, but not blood vessels, into the cornea, solving the long-standing mystery of why the cornea is normally devoid of lymphatics. Soluble VEGFR-2 was also required for normal development of lymphatics in the skin.

Importantly, administration of soluble VEGFR-2 to mice following corneal transplantation nearly eliminated graft rejection. This finding might also be applicable in kidney transplant rejection because it is known that lymphatic vessels are the culprit in the rejection of that organ as well. In addition, it challenges the prevailing dogma that abnormal blood vessels are responsible for transplant rejection.

The Ambati group also studied a childhood tumor known as lymphangioma, which is estimated to affect 1 in 50 babies and for which there is no satisfactory medical treatment. Administration of soluble VEGFR-2 blocked the growth of lymphangioma cells isolated from children with this tumor. Because this molecule spares blood vessels, it might offer a safer and more targeted treatment for this pediatric tumor. The potential benefit of modulating soluble VEGFR-2 in other diseases such lymphedema due to filariasis and or following surgery for breast cancer, as well as in tumor metastasis, are also under study.

"This paper by Dr. Ambati and his coworkers represents another in a line of highly novel and important findings from their laboratory," said Patricia A. D'Amore, Professor of Ophthalmology and Pathology, Harvard Medical School and Senior Scientist at the Schepens Eye Research Institute.

"The report of the first endogenous inhibitor of lymphangiogenesis is an exciting development and holds great therapeutic promise for a number of pathologies in which lymphatic growth is a serious complication."


'/>"/>

Contact: Ann Blackford
ann.blackford@uky.edu
859-312-3587
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Immune System Gene Discovery Sheds Light on Staph Infections
2. Cell Discovery May Bring Science Closer to Diabetes Cure
3. The Psychology of Frailty: An Identity Crisis Among the Elderly - Alzheimers Drug Discovery Foundations Dr. Howard Fillit to Co-Chair Symposium
4. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
5. Scientists Gather to Discuss Novel Uses of Caliper Life Sciences Discovery Platforms and Technology
6. Discovery Points to Regulation of Calcium Metabolism
7. IDRI Awarded $314,500 Grant From Murdock Trust to Expand TB Drug Discovery Program
8. Asthma Discovery May Lead to Better Treatments
9. Microsoft to Showcase Clinical Trial Solutions From Discovery to Approvals at Drug Information Associations 2009 Annual Meeting
10. Gaiam and Discovery Communications Announce Exclusive Licensing Deal
11. Mayo Genomic Discovery: Protecting Kidney Function During Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of ... Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities ... before the big event. The invitation-only gifting suite, held this year at the W ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and ... J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA ... Southern Nevada Healthcare System. This will be the first Fisher House in Nevada, ...
(Date:2/12/2016)... Pittsburgh, PA (PRWEB) , ... February 12, 2016 ... ... serving families of the Pittsburgh metro area, celebrates the beginning of the latest ... help children develop social skills through art. Donations to this worthy cause are ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
(Date:2/11/2016)... 2016   Health 2.0 , the premiere showcase ... announced today " 10 Year Global Retrospective ", a ... the past ten years.   --> ... 2.0 has served as the preeminent thought-leader in the ... of technologies, companies, innovators, and patient-activists through an array ...
Breaking Medicine Technology: